2026 RNDS | CAR-T Trials for NMOSD @wearesrna
2026 RNDS | CAR-T Trials for NMOSD  @wearesrna
Uploaded October 2026 | Updated November 2026, 3 hours ago
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Michael Levy, MD, PhD, of Massachusetts General Hospital, spoke about CAR-T cell therapy and the trials planned for neuromyelitis optica spectrum disorder (NMOSD) [00:00:05]. He traced CAR-T from early work on HIV to cancer treatment, and explained how T cells are re-engineered, using either a person's own cells (autologous) or cells from a healthy donor (allogeneic) [00:00:42]. He described the first autologous trial for aquaporin-4 antibody-positive NMOSD, why NMOSD was chosen, and what taking part involves [00:05:26]. Dr. Levy discussed safety concerns and the 15 years of follow-up the FDA requires [00:08:13]. He compared the two donor-cell trials, which include people who are aquaporin-4 negative, MOG antibody positive or living with autoimmune encephalitis, and explained that the trials have not yet launched [00:09:15].

Michael Levy, MD, PhD, is an Associate Neurologist at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology and Neuroinfectious Disease. He completed the MD/PhD program at Baylor College of Medicine and trained at Johns Hopkins, where he started the Neuromyelitis Optica Clinic and Research Laboratory. In 2019, he moved to Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology.

00:00 Introduction
00:14 A New Kind of Therapy
00:42 Where CAR-T Came From
01:46 What CAR-T Does
03:17 Comparison with Bone Marrow Transplant
05:26 Why NMOSD Was Chosen
06:40 Trial Design and What to Expect
08:13 Safety Concerns
09:15 Donor Cells (Allogeneic)
12:15 A Basket Study
14:26 A Second Donor-Cell Trial
18:02 Choosing Between Trials
18:44 Where the Trials Stand
2026 RNDS | CAR-T Trials for NMOSD2024 RNDS | Rare Neuroimmune Disorders: Diagnostic Criteria2024 RNDS | Management of Visual Symptoms2024 RNDS | Management of Neuropathic Pain: Medical and Surgical Options2023 RNDS | A conversation on disability and rare neuroimmune disorders2026 RNDS | New Diagnostic Criteria Update: NMOSD and Criteria Q&A202. Dr. Michael Levy203. Dr. Monica Diaz301. Significance of Brain Lesions in Pediatric MOGAD2024 RNDS | Understanding Genetics of Rare Neuroimmune Disorders2024 RNDS | Mind-Body Connection in Rare Neuroimmune Conditions: Mental Health, Fatigue & Cognition1205. Voices of SRNA Volunteers | Part 1
SRNA |

2026 RNDS | CAR-T Trials for NMOSD

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER